explore -WSS

explore

author：leisure time 2025-09-27 23:00:21 - browse：69638

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： This gene therapy has record $4.25 million price. It's saved children.

WSS

Sen. Bill Cassidy on how to lower drug prices

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

6 surprising facts about sugar

Texas board proposes rules on abortion law emergency exemption

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Rare Northern Lights show in US this week: Where and how to see it

explore

explore

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

Trump seeks lengthy delay of classified docs trial, citing upcoming election

In age of alternative facts, a scholarly course on calling out crap

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Trump demands the U.S. pay no more for drugs than other countries … again

Yancopoulos of Regeneron works to expand Dupixent success

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage insurers pressure Biden for bigger payments

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

Erich Jarvis studies song birds to learn about human stuttering

Diabetes management: Digital health tools fall short, study says

UPS workers' union leader explains what's at stake as strike edges closer

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Diabetes management: Digital health tools fall short, study says

U.K. officials, researchers try to ease path for bespoke genetic treatments

hotspot

knowledge

Wikipedia

focus